MT2013-22: A phase 2/3 study of the efficacy and safety

Project: Research project

Project Details

Description

MT2013-22: A phase 2/3 study of the efficacy and safety of hematopoietic stem cells transduced with Lenti D lentiviral vector for the treatment of childhood cerebral adrenoleukodystrophy (CCALD)
StatusFinished
Effective start/end date8/1/136/30/21

Funding

  • Bluebird Bio, Inc.

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.